HOME >> MEDICINE >> NEWS
Treatment has demonstrated improvement in physical function and kept joint damage from progressing

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., November 13, 2005 Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced data from a long-term blinded study of anti-TNF agent in patients with rheumatoid arthritis (RA) demonstrated that more than three quarters of patients treated with Enbrel (etanercept) plus methotrexate combination therapy experienced no progression of joint damage at three years. These new results from the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study will be presented at the American College of Rheumatology's (ACR) Annual Scientific Meeting in San Diego, California.

"Rheumatoid arthritis is a chronic condition requiring long-term treatment. It is critical to provide patients with treatment options that not only reduce the signs and symptoms of the disease, but also inhibit the progression of joint damage," said Dsire van der Heijde, M.D., professor of rheumatology, University of Maastricht in the Netherlands. "The TEMPO results reinforce the benefits of ENBREL and methotrexate combination therapy and underscore the importance of effective treatment."

At three years, the majority of patients taking ENBREL and methotrexate combination therapy had no progression of joint damage. These results were significantly better than those achieved in ENBREL monotherapy and methotrexate monotherapy-treated patients. Patients receiving ENBREL monotherapy also had significantly better results than patients receiving methotrexate monotherapy. Total Sharp Score was calculated by assessing changes in joint space narrowing and bone erosion as captured by radiographic imaging.

Further, additional data presented at ACR showed that improvement in physical function was higher for the ENBREL combination group than for either therapy alone. Patients treated with ENBREL combination therapy experienced a 56 percent mean improvement in Health Assessment
'"/>

Contact: Christine Cassiano, Amgen
805-447-4587
Porter Novelli
15-Nov-2005


Page: 1 2

Related medicine news :

1. Treatment for early prostate cancer associated with type of specialist seen
2. Treatment outcomes of patients with HIV and tuberculosis
3. Treatment of kidney condition requires an individualized approach
4. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
5. Treatment for homeless youth pays off in long run, study finds
6. Treatment discovered for deadly childhood disease
7. Treatment developed for patients with medically unexplained symptoms
8. Treatment drug may cause jawbone to die
9. Treatment for anorexia nervosa appears to have improved outcome
10. Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS
11. North Central Cancer Treatment Group finding ways to make treatment easier

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
Cached News: